News - AVI Biopharma Inc.
2010-05-20 11:00:00
VANCOUVER, May 20 /PRNewswire-Asia/ -- Today Insiderslab.com issues new research reports on Down by Half Purchases by company insiders such as CEOs, Presidents, Directors, and 10% shareholders.
2009-10-20 09:28:53
New publication in Molecular Therapy outlines dramatic effects in animals treated with splice switching PPMO, demonstrates promise for treatment of Duchenne muscular dystrophy.
2008-10-01 12:00:31
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Leslie Hudson, AVI's President and CEO, will present at two upcoming healthcare conferences.